Literature DB >> 10484286

L-deprenyl inhibits tumor growth, reduces serum prolactin, and suppresses brain monoamine metabolism in rats with carcinogen-induced mammary tumors.

S ThyagaRajan1, S K Quadri.   

Abstract

Previously, we have reported that L-deprenyl decreased the incidence of mammary tumors and pituitary tumors in old acyclic rats. The objective of the present study was to investigate the effects of L-deprenyl, a monoamine oxidase-B (MAO-B) inhibitor, treatment on the development and growth of tumors and on the metabolism of catecholamines and indoleamine in the medial basal hypothalamus (MBH) and the striatum (ST) of rats bearing 7,12-dimethylbenzanthracene (DMBA)-induced mammary tumors. Female Sprague-Dawley rats with DMBA-induced mammary tumors were injected (sc) daily with 0.25 mg or 5.0 mg of deprenyl/kg BW or the vehicle (saline; control) for 12 wk. Tumor diameter, tumor number, body weight, and feed intake were measured every week of the treatment period. Serum PRL and the concentrations of catecholamines, indoleamine, and their metabolites were measured by RIA and HPLC, respectively. Treatment with 5.0 mg deprenyl decreased the tumor diameter, tumor number, and serum prolactin (PRL) level. Although the body weight increased in all three groups, the body weight gain in the 5.0 mg group was smaller than that in the control and 0.25 mg groups. Deprenyl treatment had no effect on feed intake. The concentrations of dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) were decreased in the MBH and the ST, and the concentration of 5-hydroxyindoleacetic acid (5-HIAA) was decreased in the MBH of deprenyl-treated rats. Treatment with 5.0 mg deprenyl enhanced the concentrations of norepinephrine (NE) and serotonin (5-HT) in the MBH and in the ST, and the concentration of dopamine (DA) in the MBH. These results suggest that the suppression of the development and growth of DMBA-induced mammary tumors by chronic deprenyl treatment may be mediated through alterations in the synthesis and metabolism of catecholamines and indoleamine in the MBH and inhibition of PRL secretion.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10484286     DOI: 10.1007/BF02738621

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  32 in total

Review 1.  Molecular determinants of growth, angiogenesis, and metastases in breast cancer.

Authors:  R B Dickson; M E Lippman
Journal:  Semin Oncol       Date:  1992-06       Impact factor: 4.929

2.  Tyrosine hydroxylase and DOPA decarboxylase activities in the medical preoptic area and arcuate nucleus during the estrous cycle: effects of aging.

Authors:  P S Mohankumar; S Thyagarajan; S K Quadri
Journal:  Brain Res Bull       Date:  1997       Impact factor: 4.077

3.  Evidence for dopamine deamination by both type A and type B monoamine oxidase in rat brain in vivo and for the degree of inhibition of enzyme necessary for increased functional activity of dopamine and 5-hydroxytryptamine.

Authors:  A R Green; B D Mitchell; A F Tordoff; M B Youdim
Journal:  Br J Pharmacol       Date:  1977-07       Impact factor: 8.739

4.  Antitumor effect of L-deprenyl in rats with carcinogen-induced mammary tumors.

Authors:  S ThyagaRajan; S Y Felten; D L Felten
Journal:  Cancer Lett       Date:  1998-01-30       Impact factor: 8.679

5.  Does the B form selective monoamine oxidase inhibitor lose selectivity by long term treatment?

Authors:  B Ekstedt; K Magyar; J Knoll
Journal:  Biochem Pharmacol       Date:  1979-03-15       Impact factor: 5.858

6.  Deprenil: loss of selectivity for inhibition of B-type MAO after repeated treatment.

Authors:  P C Waldmeier; A E Felner
Journal:  Biochem Pharmacol       Date:  1978-03-01       Impact factor: 5.858

7.  Cognitive effects of L-deprenyl in Alzheimer's disease.

Authors:  P N Tariot; T Sunderland; H Weingartner; D L Murphy; J A Welkowitz; K Thompson; R M Cohen
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

8.  Prolactin and murine mammary tumorigenesis: a review.

Authors:  C W Welsch; H Nagasawa
Journal:  Cancer Res       Date:  1977-04       Impact factor: 12.701

9.  Cyclic changes in the release of norepinephrine and dopamine in the medial basal hypothalamus: effects of aging.

Authors:  S ThyagaRajan; P S MohanKumar; S K Quadri
Journal:  Brain Res       Date:  1995-08-14       Impact factor: 3.252

10.  The striatal dopamine dependency of life span in male rats. Longevity study with (-)deprenyl.

Authors:  J Knoll
Journal:  Mech Ageing Dev       Date:  1988-12       Impact factor: 5.432

View more
  3 in total

1.  R-deprenyl: pharmacological spectrum of its activity.

Authors:  K Magyar; B Szende; V Jenei; T Tábi; M Pálfi; E Szöko
Journal:  Neurochem Res       Date:  2010-08-20       Impact factor: 3.996

2.  Trade-off between cancer and aging: what role do other diseases play? Evidence from experimental and human population studies.

Authors:  Anatoli I Yashin; Svetlana V Ukraintseva; Igor V Akushevich; Konstantin G Arbeev; Alexander Kulminski; Lucy Akushevich
Journal:  Mech Ageing Dev       Date:  2008-03-25       Impact factor: 5.432

Review 3.  Role of dopamine in malignant tumor growth.

Authors:  S Basu; P S Dasgupta
Journal:  Endocrine       Date:  2000-06       Impact factor: 3.925

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.